UVify, the leader in swarm drone innovation, has achieved a new Guinness World Record for the most unmanned aerial vehicles (UAVs) airborne simultaneously.
INCHEON, SOUTH KOREA / ACCESSWIRE / May 3, 2024 / UVify, the leader in swarm drone innovation, has achieved a new Guinness World Record for the most unmanned aerial vehicles (UAVs) airborne simultaneously. This historic event took place in Songdo, Korea, where UVify orchestrated a breathtaking display of 5,293 IFO drones that lit up the night sky, setting a new global standard for drone technology and performance.
Guinness World Record for the most unmanned aerial vehicles (UAVs) airborne simultaneously UVify Sets New Guinness World Record with 5,293 IFO Drones in Spectacular Aerial Display
The fleet of IFO drones created intricate patterns and vibrant visuals above the awe-struck crowd, showcasing UVify's advanced programming and drone control technology. The record-breaking feat exceeded the previous record and demonstrated the immense capabilities of the IFO drones, designed specifically for high-impact entertainment and precision flying.
Hyon Lim, CEO of UVify, expressed his enthusiasm for the achievement, stating, "This event was not just about setting a world record; it was a demonstration of the innovative spirit and the relentless pursuit of excellence that drive our team at UVify. We are proud to lead the way in drone technology and to showcase our capabilities on the world stage here in Songdo."
Robert Cheek, COO of UVify, added, "Today's achievement is a milestone not only for our company but also for the broader potential of UAV technology. The flawless execution of such a large-scale drone show underlines our commitment to excellence and our ability to push the boundaries of what is possible in synchronized drone performance."
The record-setting event was meticulously planned in cooperation with local authorities and air traffic control to ensure safety and compliance with all regulatory standards. Each drone performed with precision, reflecting UVify's commitment to quality and safety in all of its technological endeavors.
The achievement was officially recognized and verified by a Guinness World Records adjudicator on-site, who commended UVify for their impeccable execution and innovative approach to aerial entertainment. This event not only places UVify at the forefront of the UAV industry but also sets the stage for future advancements in drone technology.
UVify, the leader in swarm drone innovation, has achieved a new Guinness World Record for the most unmanned aerial vehicles (UAVs) airborne simultaneously.
INCHEON, SOUTH KOREA / ACCESSWIRE / May 3, 2024 / UVify, the leader in swarm drone innovation, has achieved a new Guinness World Record for the most unmanned aerial vehicles (UAVs) airborne simultaneously. This historic event took place in Songdo, Korea, where UVify orchestrated a breathtaking display of 5,293 IFO drones that lit up the night sky, setting a new global standard for drone technology and performance.
Guinness World Record for the most unmanned aerial vehicles (UAVs) airborne simultaneously UVify Sets New Guinness World Record with 5,293 IFO Drones in Spectacular Aerial Display
The fleet of IFO drones created intricate patterns and vibrant visuals above the awe-struck crowd, showcasing UVify's advanced programming and drone control technology. The record-breaking feat exceeded the previous record and demonstrated the immense capabilities of the IFO drones, designed specifically for high-impact entertainment and precision flying.
Hyon Lim, CEO of UVify, expressed his enthusiasm for the achievement, stating, "This event was not just about setting a world record; it was a demonstration of the innovative spirit and the relentless pursuit of excellence that drive our team at UVify. We are proud to lead the way in drone technology and to showcase our capabilities on the world stage here in Songdo."
Robert Cheek, COO of UVify, added, "Today's achievement is a milestone not only for our company but also for the broader potential of UAV technology. The flawless execution of such a large-scale drone show underlines our commitment to excellence and our ability to push the boundaries of what is possible in synchronized drone performance."
The record-setting event was meticulously planned in cooperation with local authorities and air traffic control to ensure safety and compliance with all regulatory standards. Each drone performed with precision, reflecting UVify's commitment to quality and safety in all of its technological endeavors.
The achievement was officially recognized and verified by a Guinness World Records adjudicator on-site, who commended UVify for their impeccable execution and innovative approach to aerial entertainment. This event not only places UVify at the forefront of the UAV industry but also sets the stage for future advancements in drone technology.
Certified compostable materials will help packaging meet growing eco-demands.
ROMEOVILLE, IL / ACCESSWIRE / May 2, 2024 / Formerra, a leader in performance materials distribution, announces a partnership with AFC Ecoplastics to distribute its compostable products across the U.S., Canada, and Mexico. This collaboration aims to equip consumer and medical packaging applications with eco-friendly alternatives that meet stringent environmental standards and that consumers prefer.
AFC Ecoplastics compostable polymers Formerra, a leader in performance materials distribution, announces a partnership with AFC Ecoplastics to distribute its compostable products across the U.S., Canada, and Mexico.
Formerra will distribute a range of AFC's compostable resins, compounds, and colorants, including PBAT (polybutylene co-adipate co-terephthalate) and PBS (polybutylene succinate) resins. These materials are particularly suited for consumer packaged goods (CPG) applications, both rigid and film, as well as medical packaging and labware, responding to the demand for sustainable alternatives in these sectors. They have also received Health Canada and FDA approvals.
"AFC has always been at the forefront of sustainable material innovation," said Ha Le, CEO of AFC Ecoplastics. "Partnering with Formerra was a natural step in our journey to expand our reach and impact. Their robust distribution network, extensive technical support, and stellar reputation among packaging customers provide the ultimate platform for our compostable solutions."
Demand for compostable packaging is growing. Regulations such as California's SB154 are in the works in several states in the U.S. and will require single-use plastics to be either recyclable or compostable within the next several years. Produce bags and bin liners are already under regulation for compostability in California. Formerra and AFC Ecoplastics are poised to lead the market in providing viable, sustainable solutions that address regulatory and societal needs.
Mike Balasko, Director of Sustainability and Business Development at Formerra, said, "Our collaboration with AFC is a significant step forward in our sustainability initiative. These compostable materials will help our customers navigate the shifting regulatory landscape and enhance their product offerings for environmentally conscious consumers. We are committed to aiding brands in achieving both compliance and their own sustainability goals."
AFC materials are BPI certified and have also received the TÜV OK Compost industrial certification (EN 13432). Materials featuring this label are guaranteed to be biodegradable in an industrial composting plant.
Formerra will exhibit at NPE 2024 in Orlando, Florida, next week in booth S39025.
About Formerra
Formerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.
LUXEMBOURG / ACCESSWIRE / April 30, 2024 / Moolec Science SA (NASDAQ:MLEC) ("Company"; "Moolec"), a Molecular Farming food-ingredient company, announced today the granting of a patent family in the United States for its SPC2 product produced in safflower with Molecular Farming technology. This new patent adjudication will give the company, through its U.S. sole-owned subsidiary AG Biomolecules LLC, exclusivity for the use of the technology until 2041. Find the link to the patent here: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11965169.
Moolec Science Logo
Moolec, whose technological platform has been under development for more than a decade, is known for pioneering the production of a bovine protein in a crop for the food industry. With the development and commercialization of the world's first product for the food industry using Molecular Farming, Moolec shattered barriers and revealed the potential of this groundbreaking technology in the industrial biotech sector. This milestone transcended the limitations of traditional biotech practices, opening doors to innovation previously confined to pharmaceuticals.
The recently patented technology encompasses safflower plants, inclusive of their seeds, engineered with specific DNA sequences (transgenic event) aimed at improving the expression of bovine chymosin in safflower seeds.
Amit Dhingra, Moolec Science's Chief Science Officer, emphasized, "This new family of patents not only ensures intellectual property protection for our product but also represents a platform for additional opportunities for Moolec's safflower platform." He then finished by saying, "It positions us to produce new proteins and products, leveraging the unique attributes of this crop. Moolec remains committed to innovative advancements in sustainable biotechnology, driving impactful change across food industries."
Additionally, the patent extends to cover the DNA vectors utilized for transforming the safflower plant and the DNA sequences required for detecting the transgenic event.
While the patent has been successfully secured in the United States, a parallel application has been submitted in Argentina, a crucial strategic territory for Moolec's safflower technology initiatives. Although the Argentinian patent application is currently pending, the patent family boasts a lifespan extending until 2041.
About Moolec Science SA
Moolec is a science-based ingredient company leader in the use of Molecular Farming technology for food and dietary supplementation markets. The Company's mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal proteins, for good and for all. Moolec's technological approach aims to have the cost structure of plant-based solutions with the nutrition and functionality of animal-based ones. Moolec's technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company's product portfolio and pipeline leverage the agronomic efficiency of broadly used target crops like soybean, pea, and safflower to produce oils and proteins. Moolec also has an industrial and commercial R&D capability to complement the company's Molecular Farming technology. Moolec secures a growing international patent portfolio (25+, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of PhDs and Food Insiders, and operates in the United States, Europe, and South America. For more information, visit moolecscience.com and ir.moolecscience.com.
Forward-Looking Statements
This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.
The project is aimed at developing novel approaches to enhance tumor immunogenicity to broaden the population of patients who can benefit from cancer immunotherapy.
HEIDELBERG, GERMANY / ACCESSWIRE / April 30, 2024 / BioMed X, a German biomedical research institute, announces the start of a new research project in partnership with Merck at its site in Heidelberg, Germany. The main objective of the project is to develop novel immunotherapeutic strategies to overcome the immunosuppressive microenvironment of solid tumors.
Independent of tumor indication, the general immunogenicity of a tumor is positively correlated with a better prognosis and a more robust response to immune checkpoint blockade. The current paradigm envisions tumor mutations as one of the sources of immunogenic neoantigens, which are expressed and presented on the surface of the tumor cells and recognized by the immune system to mount an effective anti-tumor response. The main objective of this research group is to identify how the DNA damage response (DDR) can be harnessed to increase the immunogenicity of tumor cells. The final goal is to design novel therapeutic approaches that promote a favorable tumor microenvironment for immunotherapies.
Dr. Semih Akincilar, the scientist leading this project, explains: "Using colorectal cancer as a model, we will investigate the molecular pathways altered in immunogenic and non-immunogenic tumor clusters. This will help us to better understand the links between DNA damage response and tumor immunogenicity, with significant implications for oncological treatment."
The BioMed X Institute and Merck have been collaborating since 2013, partnering on both oncology and immunology research projects, with the end goal of developing new therapies for cancer and autoimmune diseases. "With our most recent projects in collaboration with Merck and others, we are deepening our expertise in tumor immunology," said Christian Tidona, Founder and Managing Director of the BioMed X Institute. Further details about this project can be found on the BioMed X Institute website (www.bio.mx).
About BioMed X
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
BROOKLYN, MS / ACCESSWIRE / April 25, 2024 / Jeff Martin Auctioneers, in collaboration with North American Coal, will manage the asset liquidation of The Sabine Mining Company, a lignite mine in Hallsville, Texas. This project begins with the sale of the "Yellow Rose of Texas", a Marion 8200 Dragline, along with two Easi-Miner 1224 Continuous Surface Miners, D9T, Pumps, and various other mining-related assets. This liquidation marks the start of a long-term partnership aimed at delivering outstanding value and opportunities to the international mining industry.
The "Yellow Rose" of Texas, Marion 8200 Draglin A Marion 8200 Dragline being sold by Jeff Martin Auctioneers and The Sabine Mining Company
These assets will be featured on a "Buy Now" option, which is available on the dedicated mining equipment page on Jeff Martin Auctioneers' website. In addition, Jeff Martin Auctioneers has released a special video that details the history and features of the Marion 8200 Dragline, providing potential buyers with an in-depth look at a highly sought-after item. This initiative is part of the company's commitment to enhancing buyer engagement and delivering comprehensive information about the high-value equipment available.
As an organization known for its integrity, professionalism, and dedication to client satisfaction, Jeff Martin Auctioneers invites interested parties to visit their website to view these assets. The experienced team at Jeff Martin Auctioneers is ready to assist with all aspects of the purchase process, from initial inquiry to final sale.
Jeff Martin, CEO of Jeff Martin Auctioneers, expressed pride in the partnership with North American Coal and Sabine Mine, stating, "We are proud to collaborate closely with North American Coal and Sabine Mine to bring these essential assets to the market. The sales of these assets will not only support the needs of the mining industry but will also provide a streamlined avenue for acquiring top-quality equipment for the mining industry."
Jeff Martin Auctioneers, Inc. is a premier auction company specializing in heavy construction equipment, agricultural equipment, cranes, and transportation equipment. With a continually expanding network of locations across the United States, the company's mission is to consistently provide guests with the best value-added service, maintaining the highest levels of honesty, integrity, and professionalism in the auction industry.
TEWKSBURY, MA / ACCESSWIRE / April 25, 2024 / Cambridge Isotope Laboratories, Inc. (CIL) has acquired an additional 14.8 acres of land at its Cambridge Isotope Separations (CIS) Xenia, Ohio location. Mike Steiger, Vice President of Engineering and Project Execution for CIL, stated that the new land purchase will ensure easier access to utilities for future expansion.
Cambridge Isotope Separations
This newly acquired land is situated to the west of the 20 acres purchased in 2017, which is currently the site of the North Star expansion project. This recently completed project will greatly increase 13C production and is in the startup phase. North Star is the largest 13C separation facility ever built in the world and will significantly increase CIL's capacity ensuring customer reliability for this stable isotope.
The land acquired provides the business flexibility to expand in the future as the demand continues to grow worldwide in all applications. "This investment shows CIL's commitment to innovation and growth for our customers," said CEO Cliff Caldwell. "CIL works closely with our diverse and global customers to develop and commercialize exciting, high-value applications for isotopically labeled compounds. As these applications commercialize, our customers rely on CIL's ability to scale our chemistry quickly and reliably. This land acquisition assures we have the space to continue meeting their expectations and enable these technology advancements."
The CIS facility has the world's largest 13C separation facility, is one of the world's largest 18O isotope-separation facilities and houses the largest commercial D2O re-enrichment columns in the world.
Stable isotopes, particularly deuterium, have seen an increase in commercial-scale applications in the last few decades. These applications include pharmaceuticals, semiconductors, flat panel displays, and other high-technology fields. CIL has a three-year supply contract with one Canadian source for D2O, as well as three other sources, and holds an average of an 18-24-month supply in four of CIL locations to ensure the most reliable supply.
About Cambridge Isotope Laboratories, Inc.
CIL is the world's largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL subsidiary ABX in Dresden, Germany, is active in the development and commercialization of radio isotopic-labeled compounds for the diagnosis and treatment of cancers. CIL is an operating business owned by Otsuka Pharmaceutical. The CIL business consists of two facilities in the Boston, Massachusetts, area; a large isotope-enrichment production plant in Xenia, Ohio; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France. For more information on CIL, visit isotope.com.
SAN DIEGO, CA / ACCESSWIRE / April 24, 2024 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has been selected to build production representative flight test articles of the Collaborative Combat Aircraft (CCA) for the U.S. Air Force Life Cycle Management Center's (AFLCMC) Advanced Aircraft Division. This option contract award by the Advanced Aircraft Division exercises the critical design, build, and flight test on the existing CCA contract with GA-ASI following an initial six-month phase that culminated in a successful CCA preliminary design review (PDR) earlier this year.
The CCA program aims to be a force multiplier, developing a low-cost, modular, unmanned aircraft equipped with advanced sensors or weapons and operating in collaborative teams with the next generation of manned combat aircraft.
In February 2024, GA-ASI successfully conducted the maiden flight of the XQ-67A CCA prototype aircraft validating the "genus/species" concept pioneered by the Air Force Research Laboratory (AFRL) as part of the Low-Cost Attritable Aircraft Platform Sharing (LCAAPS) program. This program focused on building several aircraft variants from a common core chassis. Since then, this prototype for CCA has successfully completed two additional test flights, laying the groundwork for a successful production and flight test program. GA-ASI's CCA production representative design is based upon the XQ-67A Off-Board Sensing Station developed by GA-ASI for the AFRL.
"The CCA program redefines the future of aviation and will shape the USAF acquisition model to deliver affordable combat mass to the warfighter at the speed of relevancy," said Mike Atwood, Vice President of Advanced Programs for GA-ASI.
"Throughout our 30-year history, GA-ASI has been at the forefront of rapidly advancing unmanned aircraft systems that support our warfighters," said GA-ASI President David R. Alexander. "The USAF is moving forward with GA-ASI due to our focused commitment to unmanned air-to-air combat operations and unmatched UAS experience, ensuring the production of the CCA aircraft at scale to deliver affordable combat mass for the warfighter."
To complement the CCA contract, GA-ASI will continue to conduct a series of autonomy and mission system tests on the MQ-20 Avenger® UAS and XQ-67A to accelerate the readiness of operational autonomy. These live flight tests will continue to demonstrate the readiness of the full mission capability to support the emerging U.S. Air Force Autonomous Collaborative Platforms (ACP).
About GA-ASI
General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable RPA systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent situational awareness. The company also produces a variety of sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas.
SAN DIEGO, CA / ACCESSWIRE / April 24, 2024 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has been selected to build production representative flight test articles of the Collaborative Combat Aircraft (CCA) for the U.S. Air Force Life Cycle Management Center's (AFLCMC) Advanced Aircraft Division. This option contract award by the Advanced Aircraft Division exercises the critical design, build, and flight test on the existing CCA contract with GA-ASI following an initial six-month phase that culminated in a successful CCA preliminary design review (PDR) earlier this year.
The CCA program aims to be a force multiplier, developing a low-cost, modular, unmanned aircraft equipped with advanced sensors or weapons and operating in collaborative teams with the next generation of manned combat aircraft.
In February 2024, GA-ASI successfully conducted the maiden flight of the XQ-67A CCA prototype aircraft validating the "genus/species" concept pioneered by the Air Force Research Laboratory (AFRL) as part of the Low-Cost Attritable Aircraft Platform Sharing (LCAAPS) program. This program focused on building several aircraft variants from a common core chassis. Since then, this prototype for CCA has successfully completed two additional test flights, laying the groundwork for a successful production and flight test program. GA-ASI's CCA production representative design is based upon the XQ-67A Off-Board Sensing Station developed by GA-ASI for the AFRL.
"The CCA program redefines the future of aviation and will shape the USAF acquisition model to deliver affordable combat mass to the warfighter at the speed of relevancy," said Mike Atwood, Vice President of Advanced Programs for GA-ASI.
"Throughout our 30-year history, GA-ASI has been at the forefront of rapidly advancing unmanned aircraft systems that support our warfighters," said GA-ASI President David R. Alexander. "The USAF is moving forward with GA-ASI due to our focused commitment to unmanned air-to-air combat operations and unmatched UAS experience, ensuring the production of the CCA aircraft at scale to deliver affordable combat mass for the warfighter."
To complement the CCA contract, GA-ASI will continue to conduct a series of autonomy and mission system tests on the MQ-20 Avenger® UAS and XQ-67A to accelerate the readiness of operational autonomy. These live flight tests will continue to demonstrate the readiness of the full mission capability to support the emerging U.S. Air Force Autonomous Collaborative Platforms (ACP).
About GA-ASI
General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable RPA systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent situational awareness. The company also produces a variety of sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas.
SAN DIEGO, CA / ACCESSWIRE / April 24, 2024 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has been selected to build production representative flight test articles of the Collaborative Combat Aircraft (CCA) for the U.S. Air Force Life Cycle Management Center's (AFLCMC) Advanced Aircraft Division. This option contract award by the Advanced Aircraft Division exercises the critical design, build, and flight test on the existing CCA contract with GA-ASI following an initial six-month phase that culminated in a successful CCA preliminary design review (PDR) earlier this year.
The CCA program aims to be a force multiplier, developing a low-cost, modular, unmanned aircraft equipped with advanced sensors or weapons and operating in collaborative teams with the next generation of manned combat aircraft.
In February 2024, GA-ASI successfully conducted the maiden flight of the XQ-67A CCA prototype aircraft validating the "genus/species" concept pioneered by the Air Force Research Laboratory (AFRL) as part of the Low-Cost Attritable Aircraft Platform Sharing (LCAAPS) program. This program focused on building several aircraft variants from a common core chassis. Since then, this prototype for CCA has successfully completed two additional test flights, laying the groundwork for a successful production and flight test program. GA-ASI's CCA production representative design is based upon the XQ-67A Off-Board Sensing Station developed by GA-ASI for the AFRL.
"The CCA program redefines the future of aviation and will shape the USAF acquisition model to deliver affordable combat mass to the warfighter at the speed of relevancy," said Mike Atwood, Vice President of Advanced Programs for GA-ASI.
"Throughout our 30-year history, GA-ASI has been at the forefront of rapidly advancing unmanned aircraft systems that support our warfighters," said GA-ASI President David R. Alexander. "The USAF is moving forward with GA-ASI due to our focused commitment to unmanned air-to-air combat operations and unmatched UAS experience, ensuring the production of the CCA aircraft at scale to deliver affordable combat mass for the warfighter."
To complement the CCA contract, GA-ASI will continue to conduct a series of autonomy and mission system tests on the MQ-20 Avenger® UAS and XQ-67A to accelerate the readiness of operational autonomy. These live flight tests will continue to demonstrate the readiness of the full mission capability to support the emerging U.S. Air Force Autonomous Collaborative Platforms (ACP).
About GA-ASI
General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable RPA systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent situational awareness. The company also produces a variety of sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas.
